<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313624</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-219-0101</org_study_id>
    <nct_id>NCT01313624</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis</brief_title>
  <acronym>AIR-BX1</acronym>
  <official_title>A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution in Subjects With Non-CF Bronchiectasis and Gram-Negative Endobronchial Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AIR-BX1 study enrolled people with non-cystic fibrosis (non-CF) bronchiectasis and
      gram-negative airway infection. Participants received two 28-day courses of either Aztreonam
      for Inhalation Solution (AZLI) or placebo taken 3 times a day. Each course was followed by a
      28-day off-drug period. Following the two blinded courses, all participants received a 28-day
      course of open-label AZLI then were followed for an additional 56 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in QOL-B Respiratory Symptoms Score at Day 28</measure>
    <time_frame>Baseline to Day 28</time_frame>
    <description>The mean (SD) change in the Respiratory Symptoms score on the Quality of Life Questionnaire-Bronchiectasis (QOL-B) was measured from baseline to the end of Course 1 (Day 28). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in QOL-B Respiratory Symptoms Score at Day 84</measure>
    <time_frame>Baseline to Day 84</time_frame>
    <description>The mean (SD) change in the Respiratory Symptoms score on the QOL-B was measured from baseline to the end of Course 2 (Day 84). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Protocol-Defined Exacerbation (PDE)</measure>
    <time_frame>Baseline to Day 112</time_frame>
    <description>Protocol-defined exacerbation was defined as an acute worsening of respiratory disease that triggered the initiation of a non-study antibiotic meeting at least 3 major criteria, or 2 major and at least 2 minor criteria.
Major Criteria: increased sputum production; increased discoloration of sputum; increased dyspnea; increased cough
Minor Criteria: fever (&gt; 38ยบ C) measured during clinic visit; increased malaise or fatigue; forced expiratory volume in 1 second (FEV1) (L) or forced vital capacity (FVC) decreased &gt; 10% from baseline; new or increased hemoptysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>AZLI-AZLI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants were randomized to receive blinded AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-AZLI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants were randomized to receive blinded placebo to match AZLI for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI for 28 days plus 56 days of treatment-free follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZLI</intervention_name>
    <description>AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily</description>
    <arm_group_label>AZLI-AZLI</arm_group_label>
    <arm_group_label>Placebo-AZLI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match AZLI administered via nebulizer three times daily</description>
    <arm_group_label>Placebo-AZLI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/Female 18 years or older with non-CF bronchiectasis

          -  Chronic sputum production on most days

          -  Positive sputum culture for gram-negative organisms

          -  Must have met lung function requirements

        Exclusion Criteria:

          -  History of CF

          -  Hospitalized within 14 days prior to joining the study

          -  Previous exposure to AZLI

          -  Pregnant, breastfeeding, or unwilling to follow contraceptive measures for the study

          -  Must have met liver and kidney function requirements

          -  Continuous oxygen use of greater than 2 liters per minute (supplemental oxygen with
             activity and at night was allowed)

          -  Treatment for nontuberculous mycobacteria infection or active mycobacterium
             tuberculosis infection within 1 year of enrollment

          -  Other serious medical conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Barker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists, LTD</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center Heart and Lung Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David Geffen School of Medicine at UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center Division of Pulmonary, Critical Care and Sleep Medicine</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landon Pediatric Foundation</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Chest Physicians</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Disease Specialists (PDS) Research</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami - Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Pulmonary Group</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary and Critical Care Associates of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardio Pulmonary Research at St. Luke's Hospital</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jamaica Hospital Medical Center</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital - Clinical Trials Center</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Roosevelt Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati / UC Health</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center - Pulmonary, Allergy &amp; Critical Care Division</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asthma Allergy &amp; Pulmonary Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Pulmonary and Sleep Center</name>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <zip>75069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamo Clinical Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Pulmonary and Critical Care</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital/ Heart and Vascular Institute Advanced Lung Disease and Transplant Center</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center/Minor James Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multicare Pulmonary Specialist</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woolcock Institute of Medical Research</name>
      <address>
        <city>Glebe</city>
        <state>New South Wales</state>
        <zip>2037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George Hospital</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>New South Wales</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Adult Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royla Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Repatriation General Hospital</name>
      <address>
        <city>Daws Park</city>
        <state>South Australia</state>
        <zip>5041</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Clinical Trials</name>
      <address>
        <city>Toorak Gardens</city>
        <state>South Australia</state>
        <zip>5065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Health</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Westmead</city>
        <state>Victoria</state>
        <zip>3194</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kelowna Respiratory and Allergy Clinic</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1W 1V3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lung Centre at Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital Pacific Lung Research</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital / Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Anil Dhar Private Practice</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de L'Universitรฉ de Montrรฉal Hotel Dieu</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2011</study_first_submitted>
  <study_first_submitted_qc>March 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2011</study_first_posted>
  <results_first_submitted>March 7, 2014</results_first_submitted>
  <results_first_submitted_qc>March 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 16, 2014</results_first_posted>
  <last_update_submitted>March 7, 2014</last_update_submitted>
  <last_update_submitted_qc>March 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled in a total of 57 study sites in the United States, Canada, and Australia. The first participant was screened on 25 April 2011. The last participant observation was on 04 June 2013.</recruitment_details>
      <pre_assignment_details>348 participants were screened and 266 were randomized and treated, and comprise the Safety Analysis Set and the Intent-to-Treat (ITT) Analysis Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZLI-AZLI</title>
          <description>Participants were randomized to receive blinded Aztreonam for Inhalation Solution (AZLI) 75 mg three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
        </group>
        <group group_id="P2">
          <title>Placebo-AZLI</title>
          <description>Participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-Label Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Analysis Set</population>
      <group_list>
        <group group_id="B1">
          <title>AZLI-AZLI</title>
          <description>Participants were randomized to receive blinded AZLI 75 mg three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
        </group>
        <group group_id="B2">
          <title>Placebo-AZLI</title>
          <description>Participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle each followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="134"/>
            <count group_id="B2" value="132"/>
            <count group_id="B3" value="266"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="12.92"/>
                    <measurement group_id="B2" value="64.9" spread="12.11"/>
                    <measurement group_id="B3" value="64.6" spread="12.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Permitted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>QOL-B Respiratory Symptom Score</title>
          <description>The Quality of Life Questionnaire-Bronchiectasis (QOL-B) overall score was scaled from 0-100 with higher scores representing better quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" spread="19.32"/>
                    <measurement group_id="B2" value="55.5" spread="19.26"/>
                    <measurement group_id="B3" value="55.2" spread="19.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in QOL-B Respiratory Symptoms Score at Day 28</title>
        <description>The mean (SD) change in the Respiratory Symptoms score on the Quality of Life Questionnaire-Bronchiectasis (QOL-B) was measured from baseline to the end of Course 1 (Day 28). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.</description>
        <time_frame>Baseline to Day 28</time_frame>
        <population>Participants in the ITT Analysis Set with scores at both baseline and Day 28 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>AZLI-AZLI</title>
            <description>Participants were randomized to receive blinded AZLI 75 mg three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Placebo-AZLI</title>
            <description>Participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in QOL-B Respiratory Symptoms Score at Day 28</title>
          <description>The mean (SD) change in the Respiratory Symptoms score on the Quality of Life Questionnaire-Bronchiectasis (QOL-B) was measured from baseline to the end of Course 1 (Day 28). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.</description>
          <population>Participants in the ITT Analysis Set with scores at both baseline and Day 28 were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="21.37"/>
                    <measurement group_id="O2" value="5.7" spread="13.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <p_value_desc>P-value was based on T-test from mixed-effect model repeated measures (MMRM).</p_value_desc>
            <method>MMRM</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>4.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in QOL-B Respiratory Symptoms Score at Day 84</title>
        <description>The mean (SD) change in the Respiratory Symptoms score on the QOL-B was measured from baseline to the end of Course 2 (Day 84). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.</description>
        <time_frame>Baseline to Day 84</time_frame>
        <population>Participants in the ITT Analysis Set with scores at both baseline and Day 84 were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>AZLI-AZLI</title>
            <description>Participants were randomized to receive blinded AZLI 75 mg three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Placebo-AZLI</title>
            <description>Participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in QOL-B Respiratory Symptoms Score at Day 84</title>
          <description>The mean (SD) change in the Respiratory Symptoms score on the QOL-B was measured from baseline to the end of Course 2 (Day 84). The QOL-B respiratory symptoms score was transformed onto a scale of 0-100, with higher scores representing a better quality of life.</description>
          <population>Participants in the ITT Analysis Set with scores at both baseline and Day 84 were analyzed.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="21.67"/>
                    <measurement group_id="O2" value="4.7" spread="17.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.56</p_value>
            <p_value_desc>P-value was based on T-test from mixed-effect model repeated measures (MMRM).</p_value_desc>
            <method>MMRM</method>
            <param_type>Difference in least squares mean</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Protocol-Defined Exacerbation (PDE)</title>
        <description>Protocol-defined exacerbation was defined as an acute worsening of respiratory disease that triggered the initiation of a non-study antibiotic meeting at least 3 major criteria, or 2 major and at least 2 minor criteria.
Major Criteria: increased sputum production; increased discoloration of sputum; increased dyspnea; increased cough
Minor Criteria: fever (&gt; 38ยบ C) measured during clinic visit; increased malaise or fatigue; forced expiratory volume in 1 second (FEV1) (L) or forced vital capacity (FVC) decreased &gt; 10% from baseline; new or increased hemoptysis</description>
        <time_frame>Baseline to Day 112</time_frame>
        <population>ITT Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>AZLI-AZLI</title>
            <description>Participants were randomized to receive blinded AZLI 75 mg three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
          </group>
          <group group_id="O2">
            <title>Placebo-AZLI</title>
            <description>Participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Protocol-Defined Exacerbation (PDE)</title>
          <description>Protocol-defined exacerbation was defined as an acute worsening of respiratory disease that triggered the initiation of a non-study antibiotic meeting at least 3 major criteria, or 2 major and at least 2 minor criteria.
Major Criteria: increased sputum production; increased discoloration of sputum; increased dyspnea; increased cough
Minor Criteria: fever (&gt; 38ยบ C) measured during clinic visit; increased malaise or fatigue; forced expiratory volume in 1 second (FEV1) (L) or forced vital capacity (FVC) decreased &gt; 10% from baseline; new or increased hemoptysis</description>
          <population>ITT Analysis Set</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">At least 50% of participants must have had a PDE in order to compute the median days to PDE. Fewer than 50% of participants in this group had a PDE, so median days to PDE could not be computed.</measurement>
                    <measurement group_id="O2" value="120" lower_limit="117.0">The 95% upper confidence interval (CI) could not be estimated due to an insufficient number of PDE events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 30 days after the last dose of study drug.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AZLI-AZLI (Double-Blind)</title>
          <description>Adverse events for this reporting group were reported from baseline to Day 112 while participants were receiving double-blind AZLI; participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
        </group>
        <group group_id="E2">
          <title>Placebo-AZLI (Double-Blind)</title>
          <description>Adverse events for this reporting group were reported from baseline to Day 112 while participants were receiving double-blind placebo; participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
        </group>
        <group group_id="E3">
          <title>AZLI-AZLI (Open-Label)</title>
          <description>Adverse events for this reporting group were reported from Day 112 to Day 196 plus 30 days while participants were receiving open-label AZLI; participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
        </group>
        <group group_id="E4">
          <title>Placebo-AZLI (Open-Label)</title>
          <description>Adverse events for this reporting group were reported from Day 112 to Day 196 plus 30 days while participants were receiving open-label AZLI; participants were randomized to receive blinded placebo to match AZLI three times daily via investigational nebulizer for 2 cycles of 28 days on treatment with each cycle followed by 28 days off treatment, followed by open-label AZLI 75 mg three times daily for 28 days plus 56 days of treatment-free follow-up.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Type IV hypersensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="76" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sputum Increased</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="122"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="132"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosures</name_or_title>
      <organization>Gilead Sciences, Inc.</organization>
      <email>ClinicalTrialDisclosures@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

